Fluticasone Propionate

• Inhaled corticosteroids in young children with episodic wheezing: a multicenter cluster RCT Pending
  2025-522694-11-00 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting
  2025-524580-21-00 Phase II/III 1 country Inmunotek S.L.
• A randomized, double-blinded clinical trial comparing the efficacy of antibiotic or inhaled corticosteroid to placebo in children's protract… Recruiting
  2025-520697-19-00 Phase III 1 country Pirkanmaan hyvinvointialue
• A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Parti… Recruiting
  2024-517991-39-00 Phase III 6 countries Teva Branded Pharmaceutical Products R&D LLC
• Effect of dual bronchodilation with umeclidinium/vilanterol on patients with COPD, hyperinflation and heart failure Recruiting
  2024-519513-61-00 Phase IV 1 country Hospital General Universitario Gregorio Maranon
• A study to evaluate the efficacy and safety of QMF149 (indacaterol acetate/mometasone furoate) versus Budesonide in children from 6 to less … Recruiting
  2022-501899-26-00 Phase III 9 countries Novartis Pharma AG
• A Trial to Evaluate EP 104GI in Adults with Eosinophilic Esophagitis (EoE) (RESOLVE) Recruiting
  2024-516689-13-00 Phase I/II 1 country Eupraxia Pharmaceuticals Inc.
• Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With… Recruiting
  2024-511382-11-00 Phase II 4 countries Novartis Pharma AG
• A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered sub… Ended
  2024-515717-17-00 Phase III 1 country Inmunotek S.L.
• A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled … Ended
  2022-502854-16-00 Phase II 3 countries Rapt Therapeutics Inc.

Showing 1–10 of 10 trials